Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
This financing round enables Cellphire to expand and accelerate the development of Thrombosomes® and support the company's groundbreaking research and development projects in the areas of targeted drug delivery, anti-thrombotic reversal, and regenerative medicine.
Lead Product(s): Platelet-based freeze-dried hemostatic agent
Therapeutic Area: Hematology Product Name: Thrombosomes
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Simcah Management
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 02, 2021